Ocuphire Pharma Debt to Equity Ratio 2010-2024 | IRD
Current and historical debt to equity ratio values for Ocuphire Pharma (IRD) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Ocuphire Pharma debt/equity for the three months ending June 30, 2024 was 0.00.
| Ocuphire Pharma Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-06-30 |
$0.00B |
$0.04B |
0.10 |
| 2024-03-31 |
$0.01B |
$0.05B |
0.13 |
| 2023-12-31 |
$0.00B |
$0.05B |
0.08 |
| 2023-09-30 |
$0.00B |
$0.05B |
0.08 |
| 2023-06-30 |
$0.01B |
$0.04B |
0.15 |
| 2023-03-31 |
$0.00B |
$0.04B |
0.10 |
| 2022-12-31 |
$0.00B |
$0.05B |
0.06 |
| 2022-09-30 |
$0.00B |
$0.01B |
0.23 |
| 2022-06-30 |
$0.00B |
$0.02B |
0.23 |
| 2022-03-31 |
$0.00B |
$0.02B |
0.19 |
| 2021-12-31 |
$0.00B |
$0.02B |
0.17 |
| 2021-09-30 |
$0.00B |
$0.02B |
0.13 |
| 2021-06-30 |
$0.00B |
$0.02B |
0.12 |
| 2021-03-31 |
$0.00B |
$0.01B |
0.24 |
| 2020-12-31 |
$0.03B |
$-0.01B |
-2.31 |
| 2020-09-30 |
$0.00B |
$0.01B |
0.55 |
| 2020-06-30 |
$0.00B |
$0.01B |
0.46 |
| 2020-03-31 |
$0.00B |
$0.01B |
0.22 |
| 2019-12-31 |
$0.01B |
$-0.01B |
-1.24 |
| 2019-09-30 |
$0.00B |
$0.01B |
0.27 |
| 2019-06-30 |
$0.00B |
$0.01B |
0.30 |
| 2019-03-31 |
$0.00B |
$0.02B |
0.22 |
| 2018-12-31 |
$0.01B |
$0.01B |
0.52 |
| 2018-09-30 |
$0.01B |
$0.01B |
1.16 |
| 2018-06-30 |
$0.01B |
$0.01B |
0.60 |
| 2018-03-31 |
$0.01B |
$0.02B |
0.51 |
| 2017-12-31 |
$0.01B |
$0.02B |
0.69 |
| 2017-09-30 |
$0.01B |
$0.02B |
0.63 |
| 2017-06-30 |
$0.01B |
$0.02B |
0.77 |
| 2017-03-31 |
$0.02B |
$0.00B |
16.34 |
| 2016-12-31 |
$0.00B |
$0.02B |
0.23 |
| 2016-09-30 |
$0.01B |
$0.02B |
0.32 |
| 2016-06-30 |
$0.01B |
$0.02B |
0.30 |
| 2016-03-31 |
$0.01B |
$0.02B |
0.49 |
| 2015-12-31 |
$0.01B |
$0.02B |
0.32 |
| 2015-09-30 |
$0.01B |
$0.02B |
0.30 |
| 2015-06-30 |
$0.01B |
$0.02B |
0.28 |
| 2015-03-31 |
$0.01B |
$0.02B |
0.30 |
| 2014-12-31 |
$0.01B |
$0.03B |
0.26 |
| 2014-09-30 |
$0.01B |
$0.03B |
0.28 |
| 2014-06-30 |
$0.01B |
$0.03B |
0.30 |
| 2014-03-31 |
$0.01B |
$0.03B |
0.47 |
| 2013-12-31 |
$0.01B |
$0.01B |
0.55 |
| 2013-09-30 |
$0.01B |
$0.01B |
0.63 |
| 2013-06-30 |
$0.01B |
$0.01B |
1.01 |
| 2013-03-31 |
$0.01B |
$0.01B |
0.59 |
| 2012-12-31 |
$0.01B |
$0.01B |
0.57 |
| 2012-09-30 |
$0.00B |
$0.01B |
0.68 |
| 2012-06-30 |
$0.00B |
$0.01B |
0.27 |
| 2012-03-31 |
$0.00B |
$0.01B |
0.35 |
| 2011-12-31 |
$0.00B |
$0.01B |
0.28 |
| 2011-09-30 |
$0.01B |
$0.01B |
0.84 |
| 2011-06-30 |
$0.01B |
$0.01B |
0.91 |
| 2011-03-31 |
$0.01B |
$0.02B |
0.59 |
| 2010-12-31 |
$0.01B |
$0.01B |
0.56 |
| 2010-09-30 |
$0.00B |
$0.02B |
0.15 |
| 2010-06-30 |
$0.00B |
$0.02B |
0.16 |
| 2010-03-31 |
$0.00B |
$0.01B |
0.24 |
| 2009-12-31 |
$0.01B |
$0.01B |
1.04 |
| 2009-09-30 |
$0.00B |
$0.01B |
0.30 |
| 2009-06-30 |
$0.00B |
$0.00B |
0.57 |
| 2009-03-31 |
$0.00B |
$0.00B |
0.79 |
| Sector |
Industry |
Market Cap |
Revenue |
|
|
$0.000B |
$0.000B |
|
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
|
